- Previous Close
0.0125 - Open
0.0135 - Bid --
- Ask --
- Day's Range
0.0127 - 0.0145 - 52 Week Range
0.0127 - 0.0145 - Volume
12,884 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
www.cero.bioRecent News: CEROW
View MoreCompare To: CEROW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CEROW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-87.57%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.49M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
3.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
8.46M